Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy and Diagnosis

Co-treatment with Radium-223 and Enzalutamide: Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) from a Prospective Multicenter Observational Study

Sabina Dizdarevic, Cora Sternberg, Fred Saad, Joaquim Bellmunt, John Logue, Sergio Baldari, Timothy Richardson, David Bottomley, Jan Kalinovsky, Inga Bayh and Oliver Sartor
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 467;
Sabina Dizdarevic
3Brighton & Sussex University Hospitals NHS Trust Brighton United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cora Sternberg
5Englander Institute for Precision Medicine Weill Cornell Medicine New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fred Saad
10University of Montreal Hospital Center Montreal QC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joaquim Bellmunt
4Dana-Farber Cancer Institute Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Logue
8The Christie NHS Foundation Trust Manchester United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergio Baldari
6Nuclear Medicine Unit University of Messina Messina Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Richardson
11Wichita Urology Wichita KS United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Bottomley
7St. James’s University Hospital Leeds United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Kalinovsky
2Bayer Consumer Care AG Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inga Bayh
1Bayer AG Wuppertal Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Sartor
9Tulane University School of Medicine New Orleans LA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

467

Objectives: REASSURE is a prospective, non-interventional, multicenter study of patients with metastatic castration-resistant prostate cancer (mCRPC); designed to assess the short- and long-term safety (7-year follow-up) of patients treated with radium-223 in real-world clinical practice. Patients received all treatments based on investigator decision. The objective of this exploratory analysis was to evaluate the real-world clinical outcomes of the combined use (concurrent or layered) of radium-223 and enzalutamide.

Methods: All patients received radium-223. Three patient groups were defined based on the timing of initiation of enzalutamide and radium-223: concurrent group (patients initiated the two drugs within 30 days of each other), layered group (patients initiated one of the two drugs ≥30 days after first treatment with the other), and naïve group (patients who were enzalutamide naïve during the observation period). Patients treated sequentially are not discussed. Descriptive statistics were generated for patient characteristics at the start of radium-223 therapy. Symptomatic skeletal event (SSE) rate, fracture rate, bone health agent (BHA) use, overall survival (OS), and cause of death were assessed. SSEs were musculoskeletal adverse events (fractures, surgery to bone, or spinal cord compression), radiotherapy to bone to relieve skeletal symptoms, or SSEs documented as a type of progression.

Results: As of November 2017, 1439 patients had received radium-223 with a median follow-up time of 9.1 months. Most of the patients treated with radium-223 were enzalutamide-naïve (n=763, 53%); layered treatment with radium-223 and enzalutamide was more frequent (n=220, 15%) than concurrent treatment (n=47, 3%). Sequential treatment was observed in 404 (28%) of the patients. SSEs were reported in 245 patients (17%) overall, in 4 (9%) patients treated concurrently with radium-223 and enzalutamide, in 35 (16%) patients treated in a layered fashion, and in 127 (17%) enzalutamide-naïve patients. Pathological bone fractures were reported in 24 (2%) patients overall, with no fractures reported in the concurrent radium-223 and enzalutamide group, 1 fracture (<1%) in the layered group, and 17 fractures (2%) in the enzalutamide-naïve group. Only 708 patients (49%) had documented BHA use at baseline. Approximately half of patients treated with radium-223 and enzalutamide also received concomitant BHAs (concurrent group, 55%; layered group, 48%). A majority of patients in all treatment groups (≥66%) received 5 or 6 injections of radium-223. Median OS was 19.7 months in the concurrent group, 15.0 months in the layered group, and 15.8 months in the enzalutamide-naïve group. [Table]

Conclusions: In this non-interventional study, concurrent or layered treatment with radium-223 and enzalutamide did not appear to increase the rate of SSEs or fractures. Patients in the concurrent treatment group seemed to have less-advanced disease than those in the layered or naïve groups, as indicated by a lower percentage of patients with prior chemotherapy. This may have contributed to the observed longer median OS and lower rates of SSEs in the concurrent group. An ongoing Phase III trial (PEACE III; NCT02194842) is investigating the combination of radium-223 and enzalutamide as first-line therapy in asymptomatic patients with mCRPC.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Co-treatment with Radium-223 and Enzalutamide: Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) from a Prospective Multicenter Observational Study
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Co-treatment with Radium-223 and Enzalutamide: Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) from a Prospective Multicenter Observational Study
Sabina Dizdarevic, Cora Sternberg, Fred Saad, Joaquim Bellmunt, John Logue, Sergio Baldari, Timothy Richardson, David Bottomley, Jan Kalinovsky, Inga Bayh, Oliver Sartor
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 467;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Co-treatment with Radium-223 and Enzalutamide: Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) from a Prospective Multicenter Observational Study
Sabina Dizdarevic, Cora Sternberg, Fred Saad, Joaquim Bellmunt, John Logue, Sergio Baldari, Timothy Richardson, David Bottomley, Jan Kalinovsky, Inga Bayh, Oliver Sartor
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 467;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Therapy and Diagnosis

  • Added value of single photon emission computed tomography (SPECT) / Computed Tomography (CT) with radioiodine whole body scan in follow up of patients with differentiated thyroid cancer
  • The association between BRAF V600E mutation of lymph node metastasis and its invasive characteristics in thyroid papillary carcinomas
  • Sequential occurrence of paraganglioma in abdomen, neck and head demonstrated by serial Ga68-DOTANOC PET-CT
Show more Oncology: Clinical Therapy and Diagnosis

Prostate Therapy I

  • Clinical Experience on 225Ac-PSMA-617 Targeted Alpha Therapy in Metastatic Castration Resistant Prostate Cancer Patients: Safety and Efficacy Results
  • Prospective analysis of circulating tumor cell mRNA in patients with mCRPC and correlation with PSMA targeted imaging and therapy: Preliminary results
Show more Prostate Therapy I

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire